With a PDUFA date of June 20, 2026 — now roughly a month away — the safety profile that Achieve Life Sciences just presented at ATS carries direct regulatory weight, not just academic interest. The ORCA-OL open-label study ran 475 adults on cytisinicline 3 mg three times daily for up to 52 weeks, with a median cumulative exposure of 361 days, and the dataset lands as the final piece of the NDA evidence package. The timing is deliberate: this is the long-term tolerability argument the FDA needed to see before approval, not a trial generating new hypotheses.
The numbers that matter most are the ones that historically derail smoking cessation drugs at the payer and prescriber level. Nausea came in at 2.5% over 52 continuous weeks — a figure that sits far below what clinicians associate with varenicline in early post-market experience and below the rates that triggered adherence collapse in earlier cessation agents. Serious adverse events affected 6.5% of participants, but 94.8% of all treatment-emergent adverse events were mild or moderate, and the discontinuation rate due to treatment-related adverse events was only 5.7%. The independent Data Safety Monitoring Committee identified no new safety signals. For a molecule competing in a space where tolerability is the primary reason patients quit the quit attempt, that profile is the core commercial argument.
The trial design deserves scrutiny alongside the results. ORCA-OL enrolled combustible cigarette users (84.6%), e-cigarette users (12.8%), and dual users (2.5%), which extends cytisinicline’s safety database into populations the pivotal Phase 3 ORCA-2 and ORCA-3 trials were not built to characterize at scale. That matters because the FDA has already granted Breakthrough Therapy designation specifically for e-cigarette cessation and awarded a Commissioner’s National Priority Voucher for that indication — a regulatory signal that the agency views this population as underserved and wants approved treatments. The ORCA-OL data begin to answer the durability question for vaping cessation, even if the vaping subgroup here is too small to carry statistical weight on its own.
The single marker to watch before June 20 is whether the FDA raises any Complete Response Letter-level questions around the e-cigarette user subgroup — specifically whether the NDA’s current label scope captures that population or whether approval arrives with a narrower smoking-only indication that forces a separate supplemental NDA for vaping cessation.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
